tirzepatide vs semaglutide side effect comparison Tirzepatide: Head-to-Head for Weight Loss & Diabetes Tirzepatide vs. Semaglutide: What You

Scand J Gastroenterol (2018) 53(12):142932

Weight regain after discontinuation is well documented, with studies showing that most patients regain 50 to 70 percent of lost weight within 12 months of stopping treatment

Negligent Design: The formulation of Tepezza contributes to an increased risk of hearing issues, including tinnitus and permanent hearing loss

Unlike older GLP-1 medications that target only one hormone, tirzepatide is the first dual GLP-1 (glucagon-like peptide 1) and GIP receptor agonist that offers greater benefits, including stronger appetite suppression, deeper metabolic changes, and more significant weight loss

These effects underscore the importance of gradual dosing escalation and adequate hydration during treatment